Table 4.
The patient’s financial capacity is evaluated by categorizing their household’s decile ranking and comparing the daily medication expenses with 20% of the household’s income
| # | Name of medicine | Affordable | Un- Affordable | Unavailable | |||
|---|---|---|---|---|---|---|---|
| Pakistan | Iran | Pakistan | Iran | Pakistan | Iran | ||
| 1 | Metformin 500 mg | 58(80.6%) | - | - | - | 14(19.4%) | 72(100%) |
| 2 | Metformin 850 mg | - | - | 12(16.7%) | - | 60(83.3%) | 72(100%) |
| 3 | Metformin 1000 mg | - | - | 51(70.8%) | - | 21(29.2%) | 72(100%) |
| 4 | Sitagliptin 50 mg | - | - | 25(34.7%) | - | 47(65.3%) | 72(100%) |
| 5 | Sitagliptin 100 mg | 16(22.2%) | - | - | - | 56(77.8%) | 72(100%) |
| 6 | Glimepiride 1 mg | - | - | 48(66.7%) | - | 24(33.3%) | 72(100%) |
| 7 | Glimepiride 2 mg | 47(65.3%) | - | - | - | 25(34.7%) | 72(100%) |
| 8 | Glimepiride 3 mg | 41(56.9%) | - | - | - | 31(43.1%) | 72(100%) |
| 9 | Glimepiride 4 mg | 42(58.3%) | - | - | - | 30(41.7%) | 72(100%) |
| 10 | Glibenclamide 5 mg | 28(38.9%) | 1(1.4%) | 5(6.9%) | - | 39(54.2%) | 71(98.6%) |
| 11 | Empagliflozin 10 mg | 1(1.4%) | - | - | - | 71(98.6%) | 72(100%) |
| 12 | Empagliflozin 25 mg | - | 1(1.4%) | 3(4.2%) | - | 69(95.8%) | 71(98.6%) |
| 13 | Dapagliflozin 5 mg | 14(19.4%) | - | - | - | 58(80.6%) | 72(100%) |
| 14 | Dapagliflozin 10 mg | 14(19.4%) | - | - | - | 58(80.6%) | 72(100%) |
| 15 | Linagliptin 5 mg | 2(2.8%) | - | - | - | 70(97.2%) | 72(100%) |
| 16 | Gliclazide 30 mg | 1(1.4%) | - | - | - | 71(98.6%) | 72(100%) |
| 17 | Gliclazide 60 mg | - | - | - | - | 72(100%) | 72(100%) |
| 18 | Empagliflozin 5 mg + Metformin 500 mg | 14(19.4%) | - | - | - | 58(80.6%) | 72(100%) |
| 19 | Empagliflozin 5 mg + Metformin 850 mg | 16(22.2%) | - | - | - | 56(77.8%) | 72(100%) |
| 20 | Empagliflozin 12.5 mg + Metformin 850 mg | 8(11.1%) | - | - | - | 64(88.9%) | 72(100%) |
| 21 | Pioglitazone 15 mg + Metformin 500 mg | 3(4.2%) | - | - | - | 69(95.8%) | 72(100%) |
| 22 | Pioglitazone 15 mg + Metformin 850 mg | 2(2.8%) | - | - | - | 70(97.2%) | 72(100%) |
| 23 | Glimepiride 1 mg + Metformin 500 mg | 31(43.1%) | - | - | - | 41(56.9%) | 72(100%) |
| 24 | Glimepiride 2 mg + Metformin 500 mg | 30(41.7%) | - | - | - | 42(58.3%) | 72(100%) |
| 25 | Sitagliptin 50 mg + Metformin 500 mg | 36(50.0%) | - | - | - | 36(50.0%) | 72(100%) |
| 26 | Sitagliptin 50 mg + Metformin 1000 mg | 35(48.6%) | - | - | - | 37(51.4%) | 72(100%) |
| 27 | Glibenclamide 5 mg + Metformin 500 mg | 29(40.3%) | - | - | - | 253(87.8%) | 72(100%) |
| 28 | Glibenclamide 5 mg + Metformin 500 mg | 4(5.6%) | - | - | - | 68(94.4%) | 72(100%) |
| 29 | Insulin NPH | 8(11.1%) | 6(8.3%) | - | - | 64(88.9%) | 66(91.7%) |
| 30 | Insulin Regular | 10(14.1%) | 23(31.9%) | - | - | 61(85.9%) | 49(68.1%) |
| 31 | Insulin Glargine | 1(1.4%) | - | - | - | 71(98.6%) | 72(100%) |
| 32 | Insulin Aspart | - | - | - | - | 72(100%) | 72(100%) |
| 33 | Insulin Mix | 7(9.7%) | 10(13.9%) | - | - | 65(90.3%) | 62(86.1%) |